NASDAQ:ABMDABIOMED Stock Price, Forecast & News

ABIOMED's stock was trading at $151.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ABMD stock has increased by 83.0% and is now trading at $276.64. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ABIOMED.

ABIOMED is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for ABIOMED.

ABIOMED, Inc. (NASDAQ:ABMD) announced its quarterly earnings data on Thursday, April, 30th. The medical equipment provider reported $0.70 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.96 by $0.26. The medical equipment provider earned $206.66 million during the quarter, compared to the consensus estimate of $209.58 million. ABIOMED had a return on equity of 18.51% and a net margin of 24.14%. ABIOMED's quarterly revenue was down .2% on a year-over-year basis. During the same period last year, the company posted $1.60 earnings per share. View ABIOMED's earnings history.

9 brokers have issued 12-month target prices for ABIOMED's stock. Their forecasts range from $152.00 to $240.00. On average, they anticipate ABIOMED's share price to reach $193.00 in the next year. This suggests that the stock has a possible downside of 30.2%. View analysts' price targets for ABIOMED.

News articles about ABMD stock have been trending negative on Thursday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ABIOMED earned a news impact score of -2.9 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about ABIOMED.

ABIOMED saw a decrease in short interest during the month of June. As of June 30th, there was short interest totaling 2,360,000 shares, a decrease of 13.6% from the June 15th total of 2,730,000 shares. Based on an average daily volume of 559,700 shares, the days-to-cover ratio is currently 4.2 days. Currently, 5.4% of the shares of the stock are sold short. View ABIOMED's Current Options Chain.

Some companies that are related to ABIOMED include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Stryker (SYK), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Steris (STE) and Insulet (PODD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Align Technology (ALGN), Netflix (NFLX), Arista Networks (ANET), Square (SQ), Paypal (PYPL), salesforce.com (CRM) and Adobe (ADBE).

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

ABIOMED's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.27%), West Coast Financial LLC (0.03%), Envestnet Asset Management Inc. (0.02%), State of Alaska Department of Revenue (0.02%), IFM Investors Pty Ltd (0.01%) and Exchange Traded Concepts LLC (0.01%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Martin P Sutter and Michael G Howley. View institutional ownership trends for ABIOMED.

ABMD stock was sold by a variety of institutional investors in the last quarter, including IFM Investors Pty Ltd, and Coe Capital Management LLC. View insider buying and selling activity for ABIOMED.

ABMD stock was purchased by a variety of institutional investors in the last quarter, including Scout Investments Inc., West Coast Financial LLC, Legacy Capital Partners Inc., Envestnet Asset Management Inc., Exchange Traded Concepts LLC, Contravisory Investment Management Inc., Cypress Capital Group, and IBM Retirement Fund. View insider buying and selling activity for ABIOMED.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABMD stock can currently be purchased for approximately $276.64.

ABIOMED has a market capitalization of $12.46 billion and generates $840.88 million in revenue each year. The medical equipment provider earns $203.01 million in net income (profit) each year or $4.74 on an earnings per share basis. ABIOMED employs 1,536 workers across the globe.

The official website for ABIOMED is www.abiomed.com.

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]